Last reviewed · How we verify
Metastatic castration-resistant prostate cancer
Approved treatments
- Zytiga · Johnson & Johnson
Zytiga blocks the production of male hormones that fuel prostate cancer growth. - Zytiga · Bukwang Pharmaceutical
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic castration-resistant prostate cancer patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic castration-resistant prostate cancer treatment landscape brief
- Metastatic castration-resistant prostate cancer treatment updates RSS
Frequently asked questions about Metastatic castration-resistant prostate cancer
What drugs treat Metastatic castration-resistant prostate cancer?
Tracked treatments include Zytiga.
What is the treatment for Metastatic castration-resistant prostate cancer?
Standard treatment for Metastatic castration-resistant prostate cancer includes Zytiga. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Metastatic castration-resistant prostate cancer patent cliff · Metastatic castration-resistant prostate cancer CI report
- Treatment: Zytiga · Johnson & Johnson
- Treatment: Zytiga · Bukwang Pharmaceutical
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing